![Eli Lilly headquarters](https://www.ibj.com/wp-content/uploads/2019/01/lilly-2col-300x200.jpg)
New research shows Lilly drug slows decline in Alzheimer’s patients
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.